AlzeCure Pharma has announced that the European Medicines Agency has granted orphan drug status to ACD440, its clinical‑stage ...
ViiV Healthcare has announced new 96‑week findings from a sub‑group analysis of the PASO DOBLE study, showing that adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results